Genelux (US:GNLX) Globenewswire·2026-01-12 21:00Core Insights - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for patients with aggressive and difficult-to-treat solid tumors [3] Company Overview - Genelux is currently evaluating its lead product, Olvi-Vec, in two U.S.-based clinical trials: OnPrime/GOG-3076, a Phase 3 trial for platinum-resistant/refractory ovarian cancer, and VIRO-25, a Phase 2 trial for non-small-cell lung cancer [3] - Additionally, Olvi-Vec is being assessed in a China-based Phase 1b/2 trial for recurrent small-cell lung cancer [3] - The company utilizes its proprietary CHOICE™ platform to develop a library of engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec [3] Upcoming Events - Key executives, including Thomas Zindrick (President, CEO, and Chairman), Matt Pulisic (CFO), and Dr. Jason Litten (CMO), will participate in a virtual fireside chat on January 19, 2026 [1] - The event will be hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners [1]